Jacob Bauer's most recent trade in BridgeBio Oncology Therapeutics Inc. was a trade of 31,675 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 16, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| BridgeBio Oncology Therapeutics Inc | Jacob Bauer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2026 | 31,675 | 31,675 | - | - | Stock Option (Right to Buy) | |
| Enliven Therapeutics Inc | Jacob Bauer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2026 | 17,126 | 17,126 | - | - | Stock Option (right to buy) | |
| BridgeBio Oncology Therapeutics Inc | Jacob Bauer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Aug 2025 | 138,193 | 138,193 | - | - | Stock Option (Right to Buy) | |
| Enliven Therapeutics Inc | Jacob Bauer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 20,491 | 20,491 | - | - | Stock Option (right to buy) |